These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 38161537)

  • 41. Chronic heart failure: the role of di vericiguat.
    Caminiti G; Sposato B; Volterrani M
    Eur Heart J Suppl; 2023 May; 25(Suppl C):C316-C318. PubMed ID: 37125270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review.
    Vrachatis DA; Papathanasiou KA; Giotaki SG; Raisakis K; Kaoukis A; Kossyvakis C; Theodorakis A; Pediotidis S; Avramides D; Siasos G; Deftereos S
    Curr Pharm Des; 2023; 29(7):509-518. PubMed ID: 36927423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy.
    Defilippi CR; Alemayehu WG; Voors AA; Kaye D; Blaustein RO; Butler J; Ezekowitz JA; Hernandez AF; Lam CSP; Roessig L; Seliger S; Shah P; Westerhout CM; Armstrong PW; O'Connor CM;
    J Card Fail; 2023 Apr; 29(4):448-458. PubMed ID: 36634811
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Optimization of Guideline-Directed Medical Therapy during Hospitalization among Patients with Heart Failure with Reduced Ejection Fraction in Daily Clinical Practice.
    Bánfi-Bacsárdi F; Muk B; Pilecky D; Duray GZ; Kiss RG; Nyolczas N
    Cardiology; 2023; 148(1):27-37. PubMed ID: 36470212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat.
    González-Juanatey JR; Comín-Colet J; Pascual Figal D; Bayes-Genis A; Cepeda JM; García-Pinilla JM; García-Quintana A; Manzano L; Zamorano JL
    Patient Prefer Adherence; 2023; 17():839-849. PubMed ID: 36999163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heart Failure With Reduced Ejection Fraction: A Review.
    Murphy SP; Ibrahim NE; Januzzi JL
    JAMA; 2020 Aug; 324(5):488-504. PubMed ID: 32749493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.
    Pieske B; Pieske-Kraigher E; Lam CSP; Melenovský V; Sliwa K; Lopatin Y; Arango JL; Bahit MC; O'Connor CM; Patel MJ; Roessig L; Morris DA; Kropf M; Westerhout CM; Zheng Y; Armstrong PW;
    Eur J Heart Fail; 2023 Jul; 25(7):1012-1021. PubMed ID: 36994634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events.
    Rao VN; Diez J; Gustafsson F; Mentz RJ; Senni M; Jankowska EA; Bauersachs J
    J Card Fail; 2023 Mar; 29(3):389-402. PubMed ID: 36529314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vericiguat in heart failure: From scientific evidence to clinical practice.
    González-Juanatey JR; Anguita-Sánchez M; Bayes-Genís A; Comín-Colet J; García-Quintana A; Recio-Mayoral A; Zamorano-Gómez JL; Cepeda-Rodrigo JM; Manzano L
    Rev Clin Esp (Barc); 2022; 222(6):359-369. PubMed ID: 35473692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective.
    Alsumali A; Djatche LM; Briggs A; Liu R; Diakite I; Patel D; Wang Y; Lautsch D
    Pharmacoeconomics; 2021 Nov; 39(11):1343-1354. PubMed ID: 34623625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction.
    Givertz MM; Stevenson LW; Costanzo MR; Bourge RC; Bauman JG; Ginn G; Abraham WT;
    J Am Coll Cardiol; 2017 Oct; 70(15):1875-1886. PubMed ID: 28982501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rationale and Design of the VITALITY-HFpEF Trial.
    Butler J; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; Wu Y; Carvalho F; Bamber L; Blaustein RO; Roessig L; Armstrong PW
    Circ Heart Fail; 2019 May; 12(5):e005998. PubMed ID: 31096775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction.
    Nakamura M; Imamura T; Kinugawa K
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.
    Trujillo ME; Arrington L; Patel Y; Passarell J; Wenning L; Blaustein RO; Armstrong PW; Meyer M; Becker C; Gheyas F
    Clin Pharmacol Ther; 2022 Nov; 112(5):1061-1069. PubMed ID: 35841202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.
    Filippatos G; Maggioni AP; Lam CSP; Pieske-Kraigher E; Butler J; Spertus J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Bamber L; Gheorghiade M; Pieske B
    Eur J Heart Fail; 2017 Jun; 19(6):782-791. PubMed ID: 28586537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy.
    Rahamim E; Nachman D; Yagel O; Yarkoni M; Elbaz-Greener G; Amir O; Asleh R
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial.
    Lam CSP; Piña IL; Zheng Y; Bonderman D; Pouleur AC; Saldarriaga C; Pieske B; Blaustein RO; Nkulikiyinka R; Westerhout CM; Armstrong PW;
    JACC Heart Fail; 2023 Sep; 11(9):1246-1257. PubMed ID: 37565973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.